Vectorite Biomedical Inc. (TPEX:4170)
Taiwan
· Delayed Price · Currency is TWD 13.75
-0.05 (-0.36%)
Apr 29, 2026, 1:57 PM CST
Vectorite Biomedical Revenue
In the year 2025, Vectorite Biomedical had annual revenue of 61.41M TWD with 6.29% growth. Vectorite Biomedical had revenue of 33.73M in the half year ending June 30, 2025, with 29.81% growth.
Revenue
61.41M
Revenue Growth
+6.29%
P/S Ratio
9.80
Revenue / Employee
n/a
Employees
n/a
Market Cap
601.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 61.41M | 3.64M | 6.29% |
| Dec 31, 2024 | 57.77M | 1.92M | 3.43% |
| Dec 31, 2023 | 55.85M | 12.94M | 30.15% |
| Dec 31, 2022 | 42.91M | 14.14M | 49.16% |
| Dec 31, 2021 | 28.77M | 4.23M | 17.22% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SynCore Biotechnology Co.,Ltd | 27.04M |
| BioLASCO Taiwan | 262.66M |
| Neith | 36.15M |
| NatureWise Biotech & Medicals | 180.29M |
| TCI GENE | 273.61M |
| Lukas Biomedical | 180.32M |
| Taiwan Advance Bio-Pharmaceutical | 371.86M |
| Level Biotechnology | 736.59M |